The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
Table 2
Multivariable-adjust OR and 95% CI of the ER, PR, HER2, and ER−/PR+ associated with BC-LuC.
PR+
ER+
HER2+
ER−/PR+
N(%)
OR (95% CI)
value
N(%)
OR (95% CI)
value
N(%)
OR (95% CI)
value
N(%)
OR (95% CI)
value
Unadjusted model
1429 (1.0)
0.94 (0.85∼1.03)
0.186
1676 (1.0)
1.07 (0.95∼1.21)
0.242
226 (0.7)
0.71 (0.61∼0.81)
<0.001
16 (0.8)
0.76 (0.47∼1.25)
0.623
Model 1
1429 (1.0)
0.88 (0.79∼0.97)
0.009
1676 (1.0)
0.93 (0.83∼1.05)
0.264
226 (0.7)
0.83 (0.72∼0.95)
0.008
16 (0.8)
0.89 (0.54∼1.46)
0.644
Model 2
1429 (1.0)
0.88 (0.80∼0.97)
0.011
1676 (1.0)
0.94 (0.83∼1.06)
0.304
226 (0.7)
0.83 (0.72∼0.96)
0.011
16 (0.8)
0.88 (0.54∼1.45)
0.623
Model 3
1429 (1.0)
0.84 (0.75∼0.93)
0.001
1676 (1.0)
0.89 (0.78∼1.02)
0.09
226 (0.7)
0.85 (0.74∼0.99)
0.034
16 (0.8)
0.91 (0.55∼1.49)
0.694
Model 4
1429 (1.0)
0.81 (0.71∼0.93)
0.002
1676 (1.0)
1.03 (0.87∼1.22)
0.718
226 (0.7)
0.83 (0.72∼0.96)
0.012
16 (0.8)
1.02 (0.61∼1.72)
0.936
Adjusted covariates: model 1 = age and sex. Model 2 = model 1+ (race, laterality, martial, and month from diagnosis treatment). Model 3 = model 2+ (AJCC, stage, CS tumor size, radiation, and chemotherapy). Model 4 = model 3+ (ER, PR, HER2, and breast subtype).
